Arcus Biosciences, Inc. RCUS 深 沪
等待开盘 02-07 09:30:00 美东时间
21.035
+1.015
+5.07%
华盛通- 最 高24.59
- 今 开20.84
- 成交量 37.58万股
- 最 低 19.91
- 昨 收 20.02
- 总市值 150.86万
- 52周最高 24.59
- 市盈率 静 29.45
- 换手率 523.99%
- 52周最低 0.00
- 委 比 23.70%
- 总股本 7.17万
- 历史最高 24.59
- 量 比 0.52
- 振 幅 23.38%
- 历史最低 0.00
- 每 手 1
- 风险率 5.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
2025-12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
2025-12-12 21:33
Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital
05:18 PM EDT, 08/27/2024 (MT Newswires) -- Arcus Biosciences (RCUS) said late Tuesday it secured a term loan facility of up to $250 million from Hercules Capital (HTGC). The loan matures in five years and can be extended to six years upon the initiation of phase 3 trials for casdatifan and quemliclu...
2024-08-28 05:18
